Proceedings of the International Symposium on Angiotensin II Antagonists, London, United Kingdom, 28th September - 1st October 1997: Angiotensin II antagonists: Efficacy, duration of action, comparison with other drugs

Journal of Human Hypertension

Volumn 12, Issue 5, 1998, Pages 271-274

  Elliott, H L ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Angiotensin II antagonists; Comparative efficacy; Dose response relationships; Duration of action

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; HYPERTENSION; PHARMACODYNAMICS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CONTROLLED CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; HUMANS; HYPERTENSION; LOSARTAN; TREATMENT OUTCOME;

EID: 0032062340     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000637     Document Type: Conference Paper

References (9)

1. Doig JK et al. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP 753/MK 954), in salt-deplete normal man. J Cardiovasc Pharmacol 1993; 21: 732-738.
2. Tikkanen I, Omvik P, Jensen HAE for the Scandinavian Study Group. Comparison of the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343-1351.
3. Gradman AH et al. A randomised, placebo-controlled, double blind, parallel study of various doses of losartan potassium compared with enalapril maleate patients with essential hypertension. Hypertension 1995; 25: 1345-1350.
4. Nelson E et al. Efficacy and safety of losartan in patients with essential hypertension. Am J Hypertens 1992; 5: 19A.
5. Azizi M et al. Is the differentiation of ATI receptor antagonists feasible in normotensive volunteers? Am Soc Hypertens, San Francisco, 28-31 May 1997 (Poster Book).
6. Andersson O, Fridman K, Wysocki M, Friberg P. Acute effects of candesartan cilexetil on the systemic and renal haemodynamics in hypertensive patients. Am Soc Hypertens, San Francisco, 28-31 May 1997 (Poster Book).
7. O'Kane KPJ, Fridman K, McInnes G. Tolerability and efficacy of candesartan cilexetil 32 mg once daily in hypertensive patients. Am Soc Hypertens, San Francisco, 28-31 May 1997 (Poster Book).
8. Elliott HL. Antihypertensive treatment with an All antagonist compared with other classes of antihypertensive drug. (Presented in Milan, June 1997, ESH Meeting).
9. Lacourciere Y et al on behalf of the Canadian Telmisartan Study Group. Comparison of the antihypertensive effects of the All antagonist telmisartan versus amlodipine in ambulatory hypertensive patients. 1st International Symposium on Angiotensin II antagonism, The Conference Centre, Kensington Town Hall, London, 28 September-1 October 1997, Abstract 11A.3.